Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary LAAD Cohort | Patients with ≥1 SAC/VAL transactions from plans of interest identified in LAAD | ||
| Secondary LAAD Cohort | Patients with SAC/VAL abandonment or rejection identified in LAAD |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients who had SAC/VAL prescriptions filled | Up to 3 months | |
| Percentage of patients who had abandoned (not accepted) SAC/VAL prescriptions | Up to 3 months | |
| Percentage of patients who had SAC/VAL prescriptions rejected by an insurance payer | Up to 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients who utilized a heart failure-related treatment in the follow-up period | Up to 12 months | |
| Time to first angiotensin-converting enzyme inhibitor (ACEi), angiotensin II receptor blockers (ARB), or angiotensin-receptor neprilysin inhibitors (ARNI, i.e., SAC/VAL) in the follow-up period |
Not provided
Inclusion Criteria:
Primary IQVIA Longitudinal Access and Adjudication Data (LAAD) Cohort (for primary objective)
For comorbidity data only:
Secondary LAAD Cohort (for secondary objective)
Exclusion Criteria:
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IQVIA | Durham | North Carolina | 27703 | United States |
Not provided
Not provided
Not provided
Not provided
| Up to 12 months |
| Percentage of patients who had a disruption in the use of ACEi/ARB/ARNI in the follow-up period | Up to 12 months |